Home>
Stocks>
Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd (INDSWFTLAB)

₹112.9▲2.87%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Ind-Swift Laboratories Ltd share Performance

₹111.05
₹116.5
₹112.9
1.64%
Low
Day's Volatility:4.83%
High
3.19%
₹64.85
₹138.45
₹112.9
42.56%
Low
52 Weeks Volatility:65.19%
High
22.63%

Returns %
1 Month Return	-9.82 %
3 Month Return	6.35 %
1 Year Return	59.75 %

Market Stats
Previous Close	₹109.75
Open	₹111.05
Volume	12.15L
Upper Circuit	-
Lower Circuit	-
Market Cap	₹648.48Cr

Company Information

IndSwift Laboratories Ltd is an Indian based company that manufactures and sell Active Pharmaceutical Ingredients (API). Established in 1995, the company has grown to encompass 25 products, the most significant being Clarithromycin Macrolide antibiotic, Atorvastatin anticholestrol, Fexofenadine antihistamine, Clopidogrel anticholestrol, Nitazoxanide antidiarrheal, Pioglitazone antidiabetic, Letrozole and Anastrozole anticancer, Venlafaxine antidepressants, and Quetipine and Aripirazole antipsychotic. IndSwift Laboratories Ltd has built a strong presence in 40 plus countries, have a subsidiary in the USA, and set up a state of the art R&D Centre with a USD 5 million investment. Additionally, the production capacity has been increased to 418.18 TPA and its product portfolio continues to expand with compounds like Dutasteride, Cinacalcet, Duloxetine, Mecloxamine citrate, Atomoxetine, Exemestane, and more. In order to explore new opportunities in pharma, the company has entered joint ventures with Wellgen Medicare LLP and Mr. Anshul Jain, and Mr. Ramesh Mehta. As of now, the company has 3 subsidiaries - IndSwift Laboratories Inc in the US, Fortune India Constructions Limited in India, and Halcyon Life Sciences Pvt Ltd in India.

Share Price: ₹112.90 per share as on 15 May, 2024 04:01 PM
Market Capitalisation: ₹648.48Cr as of today
Revenue: ₹393.33Cr as on March 2024 (Q1 24)
Net Profit: ₹238.87Cr as on March 2024 (Q1 24)
Listing date: 01 Nov, 2001
Chairperson Name: N R Munjal

Organisation	Ind-Swift Laboratories Ltd
Headquarters	Chandigarh
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Q4FY24 Net Profit Jumps 1,130% - 14 May, 2024
Pharma stock Ind-Swift Laboratories reported a 1,130% jump in net profits for Q4FY24, with revenue from operations growing by 29% YoY. The company generated a profit of Rs. 420.96 Crores in FY24 indicating a growth of 785% YoY.

Fundamentals of Ind-Swift Laboratories Ltd

Insights on Ind-Swift Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 38.95% to 49.72% in Mar 2024 quarter
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 19.42 Cr → 238.82 Cr (in ₹), with an average increase of 91.9% per quarter
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 294.63 Cr → 805.18 Cr (in ₹), with an average increase of 63.4% per quarter
NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 90.0% return, outperforming this stock by 30.2%
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 124.9% return, outperforming this stock by 84.6%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 42.00% of holdings in Mar 2024 quarter
NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 0.31% to 0.25% in Mar 2024 quarter
NEGATIVE IMPACT
Price Dip
In the last 1 month, INDSWFTLAB stock has moved down by -9.8%